Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APVO436 in Combination With Venetoclax and Azacitidine for Newly Diagnosed AML
NCT06634394Phase 1Recruiting
- Sponsor
- Aptevo Therapeutics
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mipletamig in acute myeloid leukemia (AML), sponsored by Aptevo Therapeutics. Primary endpoint: Safety, Tolerability, and Maximum Tolerated Dose (MTD) at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
mipletamig
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06634394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634394.